Pharmaceutical Executive, Dec 1, 2013 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Dec 1, 2013
Features
Executive Profile: United BioSource's Patrick Lindsay
By William Looney
For Patrick Lindsay, providing decision support across the full product life cycle is no stretch goal—it's today's fact of life
2013 Pharma and Biotech Financial Report
By Peter Young
Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.
Prescribed Behavior: Operating Under a Consent Decree
For senior executives, meeting the requirements of a Consent Decree to the satisfaction of regulators is only half of the job.
Country Report
Country Report: Canada
"Science powers commerce," Canadian Prime Minister Stephen Harper remarked in 2010. In those three words, the Prime Minister summarizes a massive effort by various stakeholders to create a "brain gain" in Canada to strengthen its positioning in the world of research and technology. Despite declining investments by big pharma in recent years, the country has created a number of innovative ways to incentivize R&D and leverage its geographic reach in the North American Market.
Column
FDA Pursues Delicate Balancing Act
By Jill Wechsler
The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.
The Best Price for the Most Revenue
By Alice Swearingen , Patrick Homer
A global life-cycle management strategy should be baked into a drug's initial price at launch, write Alice Swearingen and Patrick Homer.
Brand vs. Generic: Physicians Weigh In
By Ben Comer
Why do some doctors prescribe more generic drugs than others?
Develop Drugs for People, Not Just Bodies
A patient-centric approach to drug development delivers the benefits that actually create value, writes Charlotte Vansgaard and Mikkel Brok-Kristensen.
From the Editor
Big Stakes in Small Things
By William Looney
New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry's business model.

ADVERTISEMENT

Click here